Kouji Matsushima

Kouji Matsushima

Auto-generated profile, based on publicly available information

Kouji Matsushima

Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2021 in International Immunology
Verified
Journal Article
Open access
PDF file
TOTatsuro Ogawa
Tatsuro Ogawa
SSShigeyuki Shichino
Shigeyuki Shichino
SUSatoshi Ueha
Satoshi Ueha
KMKouji Matsushima
Kouji Matsushima
Pulmonary fibrosis (PF) is a disease in which excessive extracellular matrix (ECM) accumulation occurs in the lungs, which induces thickening of the alveolar walls, ultimately leading to the destruction of alveolar structures and respiratory failure. Idiopathic PF, the cause of which is unknown, has a poor prognosis with a median survival of 2–4 years after diagnosis. There is currently no known curative treatment. The mechanism underlying PF is thought to be initiated by the dysfunction of type II alveolar epithelial cells, which leads to ECM overproduction through the activation of fibroblasts. In addition, it has been suggested that a variety of cells contribute to fibrotic processes. In particular, clinical and basic research findings examining the roles of macrophages suggest that they may be pivotal regulators of PF. In this review, we discuss the characteristics, functions and origins of subsets of macrophages involved in PF, including resident alveolar, interstitial and monocyte-derived macrophages.

9 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YTYuichi Tsuchiya
Yuichi Tsuchiya
TSTakao Seki
Takao Seki
KKKenta Kobayashi
Kenta Kobayashi
SKSachiko Komazawa-Sakon
Sachiko Komazawa-Sakon
SSShigeyuki Shichino
Shigeyuki Shichino
HNHiroyasu Nakano
Hiroyasu Nakano
Liver fibrosis results from chronic liver injury triggered by factors such as viral infection, excess alcohol intake, and lipid accumulation. However, the mechanisms underlying liver fibrosis are not fully understood. Here, we demonstrate that the expression of fibroblast growth factor 18 (Fgf18) is elevated in mouse livers following the induction of chronic liver fibrosis models. Deletion of Fgf18 in hepatocytes attenuates liver fibrosis; conversely, overexpression of Fgf18 promotes liver fibrosis. Single-cell RNA sequencing reveals that overexpression of Fgf18 in hepatocytes results in an increase in the number of Lrat+ hepatic stellate cells (HSCs), thereby inducing fibrosis. Mechanistically, FGF18 stimulates the proliferation of HSCs by inducing the expression of Ccnd1. Moreover, the expression of FGF18 is correlated with the expression of profibrotic genes, such as COL1A1 and ACTA2, in human liver biopsy samples. Thus, FGF18 promotes liver fibrosis and could serve as a therapeutic target to treat liver fibrosis.

27 June 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
SSShigeyuki Shichino
Shigeyuki Shichino
SUSatoshi Ueha
Satoshi Ueha
SHShinichi Hashimoto
Shinichi Hashimoto
TOTatsuro Ogawa
Tatsuro Ogawa
HAHiroyasu Aoki
Hiroyasu Aoki
KMKouji Matsushima
Kouji Matsushima
Single-cell RNA-sequencing (scRNA-seq) is valuable for analyzing cellular heterogeneity. Cell composition accuracy is critical for analyzing cell–cell interaction networks from scRNA-seq data. However, droplet- and plate-based scRNA-seq techniques have cell sampling bias that could affect the cell composition of scRNA-seq datasets. Here we developed terminator-assisted solid-phase cDNA amplification and sequencing (TAS-Seq) for scRNA-seq based on a terminator, terminal transferase, and nanowell/bead-based scRNA-seq platform. TAS-Seq showed high tolerance to variations in the terminal transferase reaction, which complicate the handling of existing terminal transferase-based scRNA-seq methods. In murine and human lung samples, TAS-Seq yielded scRNA-seq data that were highly correlated with flow-cytometric data, showing higher gene-detection sensitivity and more robust detection of important cell–cell interactions and expression of growth factors/interleukins in cell subsets than 10X Chromium v2 and Smart-seq2. Expanding TAS-Seq application will improve understanding and atlas construction of lung biology at the single-cell level.

1 March 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TOTatsuro Ogawa
Tatsuro Ogawa
SSShigeyuki Shichino
Shigeyuki Shichino
SUSatoshi Ueha
Satoshi Ueha
SOShuhei Ogawa
Shuhei Ogawa
KMKouji Matsushima
Kouji Matsushima

1 January 2019 in iScience
Verified
Journal Article
Open access
KSKazushige Shiraishi
Kazushige Shiraishi
SSShigeyuki Shichino
Shigeyuki Shichino
SUSatoshi Ueha
Satoshi Ueha
TNTakuya Nakajima
Takuya Nakajima
SHShinichi Hashimoto
Shinichi Hashimoto
KMKouji Matsushima
Kouji Matsushima
Lung epithelial cells and fibroblasts are key cell populations in lung development. Fibroblasts support type 2 alveolar epithelial cells (AEC2) in the developing and mature lung. However, fibroblast-AEC2 interactions have not been clearly described. We addressed this in the present study by time course serial analysis of gene expression sequencing (SAGE-seq) of epithelial cells and fibroblasts of developing and mature murine lungs. We identified lung fibroblast-epithelial interactions that potentially regulate alveologenesis and are mediated by fibroblast-expressed ligands and epithelial cell surface receptors. In the epithelial-fibroblast co-culture alveolosphere formation assay, single intervention against fibroblast-expressed ligand or associated signaling cascades promoted or inhibited alveolosphere growth. Adding the ligand-associated molecules fibroblast growth factor 7 and Notch ligand and inhibitors of bone morphogenetic protein 4, transforming growth factor β, and glycogen synthase kinase-3β to the culture medium enabled fibroblast-free alveolosphere formation. The results revealed the essential factors regulating fibroblast-AEC2 interactions.

3 August 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CCChang-Yu Chen
Chang-Yu Chen
SUSatoshi Ueha
Satoshi Ueha
YIYoshiro Ishiwata
Yoshiro Ishiwata
SSShigeyuki Shichino
Shigeyuki Shichino
SYShoji Yokochi
Shoji Yokochi
KMKouji Matsushima
Kouji Matsushima
The expansion of intratumoral stem-like/progenitor exhausted CD8+ T (Tstem/Tpex) cells provides a potential approach to improve the therapeutic efficacy of immune checkpoint blockade (ICB). Thus, here we demonstrate a strategy to facilitate Tstem/Tpex cell expansion by combining an alarmin high-mobility group nucleosome binding domain 1 (HMGN1) peptide with programmed death-ligand 1 (PD-L1) blockade. The antitumor effects of HMGN1, anti–PD-L1, and their combined treatment were monitored in the B16F10, LLC, Colon26, or EO771 tumor–bearing mice. The comprehensive immunologic analyses, such as high-dimensional flow cytometry, transcriptome analysis, and single-cell RNA-sequencing (scRNA-seq), were used to investigate the cellular and molecular mechanisms of antitumor immune responses after treatments. We identified the immunostimulatory domain (EPKRR SARLS AKPPA KVEAK PKK) on HMGN1 and synthesized this domain as a therapeutic peptide (minP1). Combined treatment with minP1 and PD-L1 blockade induced durable tumor regression in tumor-bearing mice. minP1 increased the number of intratumoral mature DCs enriched in immunoregulatory molecules (mregDC) and enhanced their MHC class I antigen–presenting program. minP1 also synergized with PD-L1 blockade in augmenting intratumoral Tstem/Tpex cell number. Analysis of our scRNA-seq dataset by CellPhonDB suggested potential interactions between mregDCs and Tstem/Tpex cells in tumors. Our results indicate that HMGN1 peptide (minP1) serves as an immunoadjuvant to promote effective anti–PD-L1 immunotherapy with increased Tstem/Tpex cells in tumors.